Enanta Pharmaceuticals Inc
Nasdaq · Healthcare · Pharmaceutical Preparations · Watertown, MA
ENTA chart
What traders are saying about $ENTA
Latest postsEnanta Pharmaceuticals Inc news
- Enanta Starts Phase 2b/3 RSV Trial, Eyes 2027 Data
grafa.com ·
- Enanta Pharmaceuticals starts late-stage RSV trial with 2027 data due
Mugglehead Investment Magazine ·
- Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)
Yahoo Finance ·
- Enanta Pharmaceuticals, Inc. Estimates – NASDAQ:ENTA
TradingView ·
- ENTA: Enanta Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas
Stocktwits ·
- Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
Yahoo Finance ·
- Enanta Pharmaceuticals to Participate in September Investor Conferences
Yahoo Finance ·
- Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
Yahoo Finance ·
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
Yahoo Finance ·
- Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock?
Yahoo Finance ·
- Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?
Yahoo Finance ·
- Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
Yahoo Finance ·
Enanta Pharmaceuticals Inc key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $65.3M | $67.6M | $79.2M | $86.2M |
| Net income | -$81.9M | -$116.0M | -$133.8M | -$121.8M |
| Diluted EPS | $-3.84 | $-5.48 | $-6.38 | $-5.91 |
| Total assets (year end) | $329.5M | $348.6M | $428.5M | $347.5M |
| Cash and equivalents (year end) | $37.4M | $84.3M | $39.9M | $42.2M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Enanta Pharmaceuticals Inc
- Ticker
- ENTA (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Watertown, MA
- Fiscal year end
- September 30
- SEC CIK
- 1177648
Frequently asked questions
What exchange is Enanta Pharmaceuticals Inc listed on?
Enanta Pharmaceuticals Inc trades on the Nasdaq under the ticker symbol ENTA.
What industry is Enanta Pharmaceuticals Inc in?
Enanta Pharmaceuticals Inc is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Enanta Pharmaceuticals Inc headquartered?
Enanta Pharmaceuticals Inc's business address on file with the SEC is in Watertown, MA.
When does Enanta Pharmaceuticals Inc's fiscal year end?
Enanta Pharmaceuticals Inc's fiscal year ends on September 30.
How much revenue did Enanta Pharmaceuticals Inc report?
Enanta Pharmaceuticals Inc reported $65.3M in revenue for calendar year 2025, according to its SEC filings.